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Abstract
Objectives—Pre-exposure prophylaxis (PrEP) has gained a central role in prevention of HIV 
infection amongst men who have sex with men (MSM), particularly in San Francisco, California, 
USA. Programmes to enroll men in PrEP are being undertaken by a range of public and private 
organisations. PrEP will have the largest population impact if it reaches men who are most at risk 
for HIV infection, and is used in a manner that enables maximal efficacy. Access to PrEP also 
needs to be equitable. We report on the characteristics of men eligible for and using PrEP.
Methods—Data were from the 2014 implementation of National HIV Behavioural Surveillance 
(NHBS) amongst MSM in San Francisco. NHBS uses venue-based sampling as the national 
standard for sampling MSM. We compare proportions of demographic characteristics of MSM 
using versus not using PrEP who are HIV-negative and meet CDC guidelines to recommend PrEP.
Results—Overall, 64.1 % of HIV-negative MSM in San Francisco would meet guidelines for 
PrEP use, while 9.2 % of MSM overall and 14.5 % of MSM eligible were using PrEP as of 2014. 
Men using PrEP are more likely to be White and older age. There were no differences between 
men using and not using PrEP in terms of education, income and health insurance.
Conclusions—PrEP roll-out efforts should attempt to increase reach for young, Black and 
Hispanic MSM. Failure to equitably provide access to PrEP could exacerbate the US disparity in 
new HIV infections for men of colour.
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INTRODUCTION
Pre-exposure prophylaxis (PrEP) has gained a central role in prevention of HIV infection 
amongst men who have sex with men (MSM) and has been vigorously promoted in San 
Francisco, California, USA. Our city was an early site for research and the first clinical trial 
for PrEP [1], open label continuation [2], and now engaged in expanding PrEP offering 
through private [3] and public PrEP clinics [2, 4]. The safety and efficacy of the preventative 
medication have been demonstrated in clinical trials, especially amongst MSM [1, 5, 6]. 
Other research has demonstrated the acceptability and demand for PrEP amongst MSM [7–
10]. Less is known about the extent of use of PrEP amongst MSM outside the context of 
trials, demonstration projects and clinics. In particular, data need to track the use of PrEP in 
population- or community- based surveys to gauge eligibility and use and to identify 
disparities in access.
Guidance on which MSM should be recommended PrEP use has been formulated by the 
Centers for Disease Control and Prevention (CDC) [11]. Recommendations for PrEP use in 
HIV-negative MSM are: a) has an HIV-infected partner, or b) is not in a mutually 
monogamous relationship with an HIV-uninfected partner, and c) has condomless anal 
intercourse or had a sexually transmitted infection (STI) in the past six months. These CDC 
guidelines do not consider factors such as age and race/ethnicity, which are associated with 
greater rates of HIV transmission amongst MSM in the US [12].
A better understanding of who is taking up PrEP (vis-à-vis recommended criteria and 
demographic characteristics) is essential to provide information enabling public health 
officials and clinicians to better prioritise segments of populations in need of PrEP. Such 
foundational information will inform current and future efforts to stabilise HIV incidence 
and close persistent disparities. As an early epicenter of the HIV epidemic amongst MSM 
and given the vigorous scale-up of PrEP, San Francisco’s experience may presage trends 
elsewhere. We therefore undertook the present analysis to describe PrEP uptake in a 
community-based sample of MSM in San Francisco.
METHODS
Data source
We used data from the 2014 National HIV Behavioural Surveillance (NHBS) survey 
conducted in San Francisco amongst MSM [13]. Participants were recruited at community 
locations such as bars, clubs, parks, and street corners where MSM congregate, using time-
location sampling [13]. An extensive roster of venues, days and times where MSM can be 
found was compiled by the field team. From that roster, venues were selected randomly 
without replacement to construct a month long sampling calendar. After venues were 
selected, days and times were randomly selected for each venue and scheduled for sampling 
events. At each of the four-hour sampling events, study staff enumerated all potentially 
eligible men at or entering the venue and systematically approached, screened and enrolled 
eligible men. Men were eligible if they lived in the San Francisco division of the San 
Francisco metropolitan statistical area, were 18 or older, and identified as gay or bisexual or 
have had sex with another man in the past 12 months. Men who agreed to participate gave 
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oral informed consent and completed an interviewer administered survey on a tablet 
computer.
Measures
The current paper focuses on the prevalence of PrEP eligibility and use by different 
populations of MSM during the time period following the introduction of PrEP to MSM in 
San Francisco. That is, the survey was conducted in 2014, two years after FDA licensing of 
PrEP [14]. Many MSM in San Francisco participated in the blinded and open label trials and 
demonstration projects prior to licensure. The CDC guidelines were used to classify the 
proportion of MSM recommended for PrEP in the population as a whole and within 
demographic groups [11]. Specifically, we classified HIV-negative respondents as meeting 
guidelines for PrEP over the 12 months prior to the survey if they reported having an HIV-
positive partner or were not in a mutually monogamous relationship with an HIV-negative 
partner AND reported condomless anal sex or an STI in the past 12 months. Of note, the 
CDC guidelines for STI history are measured with the last six months as the recall period; 
unfortunately our recall period was the last 12 months.
After classifying men by PrEP eligibility, we further classified them by their self-reported 
PrEP use with the following introduction and question: “Researchers are studying whether 
anti-HIV medicine (also called antiretrovirals) -- a pill -- could possibly be taken to prevent 
HIV infection. “In the past 12 months, have you taken anti-HIV medicines before sex 
because you thought it would keep you from getting HIV?”. Therefore, our definition of 
PrEP use potentially capture men who were prescribed PrEP by a clinician as well men who 
used antiretrovirals from another informal source (e.g., a friend or sex partner). [15, 16]
Analysis
Analysis was guided by the null hypothesis that PrEP use would be equally distributed 
amongst MSM in San Francisco by demographic characteristics (e.g., age, race/ethnic, 
education, income) and by health insurance status (as an indicator of access to care) amongst 
those eligible for PrEP. We restricted analysis to men who self-reported being HIV-
uninfected. We first examined the number and per cent of PrEP-eligible individuals in the 
groups of interest, compared by Fisher’s exact test. We then compared PrEP use amongst 
those eligible in bivariate and multivariate models to estimate risk ratios and corresponding 
95 % confidence intervals. We used generalised linear models with a Poisson family and a 
log link, and obtained robust standard errors. In our multivariate models, we adjusted for age 
and race/ethnicity (the model for the association with age group was only adjusted for race/
ethnicity, and vice versa). All analysis was conducted using R (R version: 3.2.0). We used a 
significance level of 0.05 for all statistical tests.
Ethical review and approval was obtained from the University of California, San Francisco, 
Committee on Human Research (IRB approval # 084556).
RESULTS
San Francisco’s 2014 implementation of NHBS MSM recruited 411 MSM. Of those, 301 
(73.2 %) self-reported being HIV-negative (Table 1). A majority was between 25 and 44 
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years old (60.5 %), White (54.8 %), had at least some college education (86.4 %), or earned 
$50,000 USD per year or greater (53.4 %). Fully 87.7 % of HIV-negative MSM reported 
having health insurance. A large proportion of men (64.1 %, 193 men) met the CDC 
recommended guidelines for PrEP. Age was associated with meeting PrEP guidelines; 
80.0 % of young MSM age 18 to 24 years were eligible compared to 28.6 % of those 55 and 
older (p<0.001). No differences in the proportions meeting the guidelines for PrEP were 
noted by race/ethnicity, education level, income, and health insurance status.
Overall 30 men (9.9 %) reported using PrEP at some point in the past 12 months. Of note, 
two men (0.7 % of the sample of HIV-uninfected men) were reportedly using PrEP but did 
not fall under one of the guidelines for PrEP use. Amongst men using PrEP, the majority 
reported receiving PrEP from their doctor (93.3%). Amongst men who met recommended 
guidelines, PrEP use significantly differed by age (p=0.04) and race/ethnicity (p=0.02) 
(Table 2). No eligible individuals in the youngest age group (18–24 years) reported PrEP 
use, whereas 30 % of eligible men 55 years of age or older reported PrEP use. Compared to 
White MSM, fewer in other racial/ethnic groups reported PrEP use. In particular, eligible 
Hispanic men were less likely than eligible White men to report PrEP use (4.3 % vs. 22.9 %, 
respectively, age-adjusted risk ratio [RR] comparing Hispanics to Whites 0.2, 95 % 
confidence interval [CI] 0.0–0.8). Eligible Asian men and eligible Black men were also less 
likely to report PrEP use: 7.1 % of eligible Asian men and 7.7 % of eligible Black men 
reported PrEP use, compared to the 22.9 % of eligible White MSM. Eligible White men 
were over four times as likely as eligible non-White men to use PrEP (age-adjusted RR: 4.4, 
95 % CI 1.6–11.9; results not shown in table).
In terms of willingness to use PrEP, 145 (48%) of the HIV-negative men reported that they 
would be willing to take PrEP. The proportion of each race/ethnicity group willing to take 
PrEP was similar (ranging from 43% to 54%).
DISCUSSION
While nearly two-thirds of MSM in San Francisco are eligible for PrEP, fewer than one in 
ten were using this prevention method two years after licensure and four years after it was 
found safe and efficacious [1, 14]. Using a published estimate of the size of the HIV 
uninfected MSM population in San Francisco [17] we estimate that 32,453 MSM would fall 
under the CDC guidelines of whom 4,708 were using PrEP in 2014. In other words, an 
additional 27,745 MSM in San Francisco would meet the guidelines but were not using 
PrEP.
While we found little difference in willingness to take PrEP across racial groups, we also 
found disparities in that PrEP use was disproportionately lower amongst young MSM and 
MSM of colour, particularly Black and or Hispanic men. Having health insurance was not 
correlated with PrEP use, suggesting that broad access to health care does not account for 
these disparities. Other studies have noted barriers to PrEP use amongst Black and Hispanic 
MSM, including perception of side effects [18] and cost [19]. A study of STI clinic 
attendees, including San Francisco, found MSM of colour less likely to have heard of PrEP 
and less likely self-refer for PrEP compared to White MSM [9]. Moreover, our data suggest 
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that there is a discrepancy in the fact that similar proportions were willing to use PrEP by 
race/ethnic groups yet a paucity of Black and Latino MSM who were using PrEP at the time 
of the survey. A limitation of our behavioural surveillance-oriented survey is that we did not 
ask the specific reasons why persons did not use PrEP. We can nonetheless corroborate the 
potentially emerging PrEP disparity for these groups in the wider population.
Of course, our analysis has other limitations. First, as our data originate from a cross section 
survey we cannot ascribe causality to PrEP use. Indeed, our analysis does not include risk 
behaviours as temporality (e.g. cause before effect) cannot be established. However, the 
comparisons between those that are using and those that are not using PrEP is informative to 
describe PrEP use in a community-based sample and therefore also closer to a real-world 
settings. For example, our data can be used to advocate for programmes prioritising young 
and minority MSM. Second, our data are from 2014 when only a short time from licensure 
in 2012. The proportion of MSM using PrEP in San Francisco may well be larger at the time 
of this analysis. Third, although NHBS uses venue-based sampling as the national standard 
to sample MSM it is possible that our data miss some segments of the population or include 
those who may be more or less likely to use PrEP. Fourth, sample sizes are small given the 
low level of PrEP uptake so far, even in San Francisco where promotion has been vigorous. 
Collectively, these limitations highlight an important area for future research as PrEP use 
becomes more widespread. Lastly, our data are from San Francisco and do not reflect what 
may be occurring in other places in the US or internationally. For example, the demographic 
makeup of San Francisco MSM may differ from other populations of MSM in the U.S. and 
internationally. Unfortunately, sexual orientation is not yet included in the US Census and 
the sizes and make-up of MSM populations in the US are uncertain. However, with San 
Francisco being an early, vocal adopter of PrEP [4], our findings may provide a glimpse of 
one scenario that may play out elsewhere.
In conclusion, these findings call attention to the need to further monitor the rollout and 
uptake of PrEP in communities of MSM where it is recommended. PrEP uptake efforts 
should continue to attempt to reach Black and Latino MSM. If Black and Latino MSM do 
not take up PrEP use while White men do, it is possible that a greater share of new HIV 
diagnoses may occur amongst men of colour, exacerbating noted HIV disparities [12, 20, 
21].
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KEY POINTS
• In the first two years after licensure for preventing HIV 
infection, Pre-exposure prophylaxis (PrEP) was being 
used by 9.3 % of HIV-negative MSM in San Francisco.
• PrEP was less likely to be used by MSM of colour, 
particularly Black and Hispanic, and by younger MSM.
• The emerging pattern of PrEP use may foreshadow a 
further widening disparity in HIV prevalence amongst 
MSM of colour in the US unless measures to reach these 
populations are prioritised.
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Table 2
Profile of PrEP users among MSM eligible for PrEP, San Francisco, 2014
Per cent using PrEP p Risk ratio (95 % CI) Adjusted risk ratio (95 % CI)*
Age group (years) 0.04
 18–24 0.0 0.0 (NA) 0.0 (NA)
 25–34 12.6 0.4 (0.1, 1.3) 0.6 (0.2, 1.9)
 35–44 23.3 0.8 (0.3, 2.3) 1.1 (0.4, 3.3)
 45–54 13.8 0.5 (0.1, 1.7) 0.6 (0.2, 2.0)
 55+ 30.0 Reference Reference
Race/ethnicity 0.02
 Asian 7.1 0.3 (0.0, 2.1) 0.4 (0.1, 2.8)
 Black 7.7 0.3 (0.0, 2.3) 0.3 (0.0, 2.4)
 Hispanic 4.3 0.2 (0.0, 0.8) 0.2 (0.0, 0.8)
 Other 0.0 0.0 (NA) 0.0 (NA)
 White 22.9 Reference Reference
 Mixed 0.0 0.0 (NA) 0.0 (NA)
Education 0.26
 Grade 12 or lower 3.8 Reference Reference
 Some college 12.5 3.2 (0.4, 24.7) 1.7 (0.2, 13.3)
 Bachelor’s degree 18.0 4.7 (0.6, 34.5) 1.8 (0.2, 13.3)
 Any post-graduate 19.0 5.0 (0.7, 37.4) 1.5 (0.2, 12.6)
Annual income 0.18
 $0–25,000 12.0 Reference Reference
 $25,000–50,000 7.3 0.6 (0.2, 2.3) 0.5 (0.1, 2.2)
 $50,000+ 19.0 1.6 (0.7, 3.7) 1.0 (0.4, 2.1)
Have health insurance 1.00
 Yes 14.5 1.0 (0.4, 2.7) 0.9 (0.3, 2.4)
 No 14.3 Reference Reference
*Adjusted for age and race (model for association with age is adjusted for race while model for association with race is adjusted for age).
Abbreviations: CI, confidence interval; NA, not applicable.
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